champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Company profile
Ticker
CSBR
Exchange
Website
CEO
Ronnie Morris
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHAMPIONS BIOTECHNOLOGY, INC., CHAMPIONS SPORTS INC
SEC CIK
Corporate docs
IRS number
521401755
CSBR stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
14 Mar 24
8-K
Champions Oncology Reports Quarterly Revenue of $12.0 Million
12 Mar 24
10-Q
2024 Q2
Quarterly report
13 Dec 23
8-K
Champions Oncology Reports Quarterly Revenue of $11.6 Million
12 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
19 Oct 23
8-K
Champions Oncology Announces the Addition of Brady Davis as President
17 Oct 23
10-Q
2024 Q1
Quarterly report
13 Sep 23
8-K
Champions Oncology Reports Quarterly Revenue of $12.6 Million
13 Sep 23
DEFA14A
Additional proxy soliciting materials
28 Aug 23
DEF 14A
Definitive proxy
28 Aug 23
Transcripts
CSBR
Earnings call transcript
2024 Q3
12 Mar 24
CSBR
Earnings call transcript
2024 Q2
12 Dec 23
CSBR
Earnings call transcript
2024 Q1
13 Sep 23
CSBR
Earnings call transcript
2023 Q4
24 Jul 23
CSBR
Earnings call transcript
2023 Q3
15 Mar 23
CSBR
Earnings call transcript
2023 Q2
14 Dec 22
CSBR
Earnings call transcript
2023 Q1
9 Sep 22
CSBR
Earnings call transcript
2022 Q4
21 Jul 22
CSBR
Earnings call transcript
2022 Q3
16 Mar 22
CSBR
Earnings call transcript
2022 Q2
14 Dec 21
Latest ownership filings
4
Brady Davis
1 Apr 24
SC 13G
TOCQUEVILLE ASSET MANAGEMENT L.P.
12 Feb 24
4
Daniel Newman Mendelson
16 Jan 24
4
Daniel Newman Mendelson
12 Jan 24
4
Daniel Newman Mendelson
11 Jan 24
4
Daniel Newman Mendelson
10 Jan 24
4
Daniel Newman Mendelson
9 Jan 24
4
Daniel Newman Mendelson
8 Jan 24
4
Daniel Newman Mendelson
8 Jan 24
4
JOEL ACKERMAN
5 Jan 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.51 mm | 5.51 mm | 5.51 mm | 5.51 mm | 5.51 mm | 5.51 mm |
Cash burn (monthly) | (no burn) | 442.75 k | 686.67 k | 800.92 k | (no burn) | 210.08 k |
Cash used (since last report) | n/a | 2.50 mm | 3.87 mm | 4.51 mm | n/a | 1.18 mm |
Cash remaining | n/a | 3.02 mm | 1.64 mm | 998.13 k | n/a | 4.33 mm |
Runway (months of cash) | n/a | 6.8 | 2.4 | 1.2 | n/a | 20.6 |
Institutional ownership, Q2 2023
47.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 7 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 36.05 bn |
Total shares | 6.49 mm |
Total puts | 208.20 k |
Total calls | 21.20 k |
Total put/call ratio | 9.8 |
Largest owners | Shares | Value |
---|---|---|
Battery Management | 2.42 mm | $15.45 bn |
NEA Management | 1.71 mm | $10.93 bn |
West Elk Partners | 676.94 k | $6.40 mm |
Tocqueville Asset Management | 665.43 k | $4.25 bn |
Renaissance Technologies | 124.89 k | $797.00 k |
BLK Blackrock | 117.14 k | $747.35 mm |
Essex Investment Management | 111.34 k | $710.35 mm |
Dimensional Fund Advisors | 87.67 k | $551.45 mm |
AMP Ameriprise Financial | 84.83 k | $533.59 mm |
Vanguard | 68.01 k | $433.88 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.5 | 1,000 | 6.50 k | 198,625 |
11 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.27 | 2,000 | 12.54 k | 197,625 |
10 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.31 | 2,944 | 18.58 k | 195,625 |
9 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.25 | 3,000 | 18.75 k | 192,681 |
8 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.15 | 1,000 | 6.15 k | 189,681 |
News
Craig-Hallum Downgrades Champions Oncology to Hold
13 Mar 24
Champions Oncology: Q3 Earnings Insights
12 Mar 24
Champions Oncology Q3 Adj $(0.16) Misses $(0.15) Estimate, Sales $12.02M Miss $13.48M Estimate
12 Mar 24
Earnings Scheduled For March 12, 2024
12 Mar 24
Earnings Outlook For Champions Oncology
11 Mar 24